Nationwide survey analysis of esophagogastric varices in portal hypertension based on endoscopic management in China

作者：Xing Wang, B. Y. Hu, Yiling Li, Weichun Lin, Zhijie Feng, Yanjing Gao, Zhining Fan, Feng Ji, Bing-Rong Liu, Jinhai Wang, Wenhui Zhang, Tong Dang, Hong Xu, Derun Kong, Lili Yuan, Liang-Bi Xu, Shengjuan Hu, Liangzhi Wen, Ping Yao, Yunxiao Liang, Xiaodong Zhou, Huiling Xiang, Xiaowei Liu, Xiaoquan Huang, Yinglei Miao, Xiaoliang Zhu, Dean Tian, Feihu Bai, Ji-Tao Song, Ligang Chen, Yangzhen Bian Ba, Yingcai Ma, Yifei Huang, Bin Wu, Xiaolong Qi · 发表于：Portal hypertension & cirrhosis · 年份：2024 · DOI：10.1002/poh2.91 · 被引用次数：3 · 研究领域：Liver Disease and Transplantation、Liver Disease Diagnosis and Treatment、Organ Transplantation Techniques and Outcomes

Abstract Aims The endoscopic treatment of esophagogastric varices is challenging, and the nationwide application of endoscopic therapies for various types of esophagogastric varices and different clinical scenarios remains unclear. This study investigated the use of endoscopic therapy for portal hypertension in China. Methods This study used a questionnaire survey initiated by the Liver Health Consortium in China to investigate the use of endoscopic therapies for portal hypertension. Questionnaires were released online from January 30, 2023 to February 28, 2023 and filled out by chief physicians or senior instructors responsible for endoscopic therapies in participating hospitals across 31 provinces (autonomous regions and municipalities) in China. Comparisons of guideline adherence between primary and referral medical centers were performed using the chi‐square test or Fisher's exact test. Results In total, 836 hospitals participated in the survey. For primary and secondary prophylaxis of esophagogastric variceal bleeding (EGVB), adherence to the national guidelines was 72.5% (606/836) and 39.2% (328/836), respectively. Significant differences were observed in the rate of adherence between the primary and referral centers for primary (79.9% [111/139] vs. 71.0% [495/697], p = 0.033) and secondary prophylaxis (27.3% [38/139] vs. 41.6% [290/697], p = 0.002). Of the hospitals, 78.2% (654/836) preferred endoscopic therapies for acute EGVB, and the timing of endoscopy was usually ...